Komori
CellSource (4880) · InitiativeFirst stated

Launch of contract processing services for PFC-FD™ (2.0)

First written in FY2024-Q2. . Latest entry: FY2024-Q2.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Launch of an outsourced processing service for autologous blood-derived cytokine PFC-FDA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2024-Q2First statedAnnual report

    「We began contract processing of PFC-FD™ (2.0), an autologous blood-derived cytokine containing a higher concentration of growth factors, which are expected to have anti-inflammatory and tissue-repair effects, and a reduced amount of inflammatory cytokines compared with the previous product.」

    The filing for the first time described the launch of contract processing for PFC-FD™ (2.0), an autologous blood-derived cytokine containing more growth factors and fewer inflammatory cytokines than the previous product.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for CellSource yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Launch of contract processing services for PFC-FD™ (2.0) | CellSource Co.,Ltd. (4880) | Komori